000309938 001__ 309938
000309938 005__ 20260220120944.0
000309938 0247_ $$2doi$$a10.1245/s10434-026-19192-1
000309938 0247_ $$2pmid$$apmid:41699355
000309938 0247_ $$2ISSN$$a1068-9265
000309938 0247_ $$2ISSN$$a1534-4681
000309938 037__ $$aDKFZ-2026-00387
000309938 041__ $$aEnglish
000309938 082__ $$a610
000309938 1001_ $$0P:(DE-HGF)0$$aGiehl-Brown, Esther$$b0
000309938 245__ $$aIs Extended Lymphadenectomy in Biliary Tract Cancers Justified? A Retrospective Comparative Study of Gallbladder Cancer, Perihilar and Intrahepatic Cholangiocarcinoma.
000309938 260__ $$aBerlin [u.a.]$$bSpringer$$c2026
000309938 3367_ $$2DRIVER$$aarticle
000309938 3367_ $$2DataCite$$aOutput Types/Journal article
000309938 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771510439_3004203
000309938 3367_ $$2BibTeX$$aARTICLE
000309938 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309938 3367_ $$00$$2EndNote$$aJournal Article
000309938 500__ $$a#NCTZFB9# / epub
000309938 520__ $$aThe oncologic value of lymphadenectomy (LND) in biliary tract cancers (BTC) remains controversial. While guidelines recommend retrieval of ≥ 6 lymph nodes to ensure accurate staging, evidence for a therapeutic survival benefit is limited.We retrospectively analyzed 253 consecutive resections for intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma (pCCA), and gallbladder carcinoma (GBC) at a high‑volume hepatobiliary center from a prospectively maintained database (2013-2023). Patients were stratified into no (0 nodes), limited (1-5 nodes), and extended (≥ 6 nodes) LND. Postoperative morbidity, recurrence-free survival (RFS), and overall survival (OS) were assessed with uni- and multivariable models.LND was performed in 47% of patients and extended LND in 52.9%. Clavien-Dindo grade ≥ III complications occurred in 69.8% with LND ≥ 6 compared with 46.4% with LND1-5 and 41.8% with no LND (p < 0.001), with longer ICU and hospital stays and more septic and pulmonary events. On multivariable analysis, LND ≥ 6 was not an independent predictor of morbidity in the overall cohort, but in the subgroup of major resections (OR 2.79, 95% CI 1.121-6.955, p = 0.027). LND extent had no independent impact on OS or RFS.Extended LND was associated with a higher rate of postoperative complications and was an independent risk factor in patients undergoing major hepatectomy. However, no clear survival benefit was observed. These findings may suggest that the role of LND in BTC may be primarily diagnostic and that more selective, biology-driven approaches should be considered. Prospective studies are needed for validation.
000309938 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309938 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309938 650_7 $$2Other$$aBiliary tract cancer
000309938 650_7 $$2Other$$aLymphadenectomy
000309938 650_7 $$2Other$$aPostoperative morbidity
000309938 650_7 $$2Other$$aRecurrence-free survival
000309938 650_7 $$2Other$$aStaging accuracy
000309938 7001_ $$aNikbakhsh, Rajan$$b1
000309938 7001_ $$aBendig, Sarah$$b2
000309938 7001_ $$0P:(DE-HGF)0$$aRadulova-Mauersberger, Olga$$b3
000309938 7001_ $$0P:(DE-HGF)0$$aSchweipert, Johannes$$b4
000309938 7001_ $$0P:(DE-HGF)0$$aWeitz, Jürgen$$b5
000309938 7001_ $$0P:(DE-HGF)0$$aRiediger, Carina$$b6
000309938 773__ $$0PERI:(DE-600)2074021-9$$a10.1245/s10434-026-19192-1$$pnn$$tAnnals of surgical oncology$$vnn$$x1068-9265$$y2026
000309938 909CO $$ooai:inrepo02.dkfz.de:309938$$pVDB
000309938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000309938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000309938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000309938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000309938 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309938 9141_ $$y2026
000309938 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000309938 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-17$$wger
000309938 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-17$$wger
000309938 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN SURG ONCOL : 2022$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000309938 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-17
000309938 9201_ $$0I:(DE-He78)DD04-20160331$$kDD04$$lKoordinierungsstelle NCT Dresden$$x0
000309938 980__ $$ajournal
000309938 980__ $$aVDB
000309938 980__ $$aI:(DE-He78)DD04-20160331
000309938 980__ $$aUNRESTRICTED